Drug Trial Radar · NCT03232073
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
877
Actual
Start
Jul 5, 2017
Primary completion
Jan 16, 2024
Study completion Jan 16, 2024
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS). The AC-058B303 study is the long-term extension for the core study AC-058B301. The purpose of this long term extension of the core study AC-058B301 is to characterize the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with RMS.
Conditions
- Multiple Sclerosis
Interventions
PonesimodDrug
Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Confirmed Relapse Rate (ARR)Time frame: From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Time From Core Study Randomization to First Confirmed RelapseTime frame: From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Time to First 12-week Confirmed Disability Accumulation (CDA)Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Time to First 24-week Confirmed Disability Accumulation (CDA)Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Percentage of Participants With Absence of RelapsesTime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Change From Baseline in Expanded Disability Status Scale (EDSS)Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of StudyTime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of StudyTime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI)Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
- Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRITime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Number of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRITime frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
- Cumulative Number of New or Enlarging T2 Lesions Measured by MRITime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Change From Baseline in Volume of MRI Lesions (T2 Lesions and T1 Hypointense Lesions)Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
- Number of Participants With Absence of MRI Lesions (Gd+ T1 Lesions, New or Enlarging T2 Lesions)Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
- Percentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs)Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
- Number of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) AbnormalitiesTime frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
- Actual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart RateTime frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
- Actual Values of 12-lead ECG Measurements up to End of Study Treatment: PR, QRS, QT, QTcB, QTcFTime frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
- Change in Heart Rate (HR) From Baseline up to End of Study TreatmentTime frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
- Change in PR, QRS, QT, QTcB, QTcF From Baseline up to End of Study TreatmentTime frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
- Absolute Values in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) ValuesTime frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
- Percent Change in (FEV1) and Forced Vital Capacity (FVC) From Baseline (%)Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
- Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
- Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
- Number of Participants With AE Leading to Premature Discontinuation of Study TreatmentTime frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
- Number of Participants With Treatment-emergent Decrease From Baseline >20% and >30% in FEV1 or FVCTime frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
- Number of Participants With Treatment-emergent Decrease of >20% Points in Percent Predicted FEV1 and FVC From BaselineTime frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
- Number of Participants With a Decrease of >=200 mL or >=12% in FEV1 or FVC From Baseline to EOTTime frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
- Change in FEV1 and FVC (% Predicted) From Baseline to End of Treatment (EOT)Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
- Change in FEV1 and FVC (% Predicted) From Baseline to End of Study (EOS)Time frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
- Absolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From BaselineTime frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
- Change in DL[CO] (% Predicted) From Baseline to EOTTime frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
- Change in DL[CO] (% Predicted) From Baseline to EOSTime frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
Locations
148 sites in 28 countries. Site status is shown where the registry gives one.
The Research Center of Southern California, LLC
Carlsbad, California
The Neurology Group
Pomona, California
Mountain View Clinical Research
Denver, Colorado
Neurology Associates of Ormond Beach
Ormond Beach, Florida
University of South Florida
Tampa, Florida
Josephson Wallack Munshower Neurology, PC
Indianapolis, Indiana
Raleigh Neurology Associates
Raleigh, North Carolina
Ohio Health
Columbus, Ohio
Advanced Neurosciences Institute
Franklin, Tennessee
Grodno University Hospital
Grodno, Belarus
Minsk City Clinical Hospital 5
Minsk, Belarus
Republican Scientific Clinical Centre
Minsk, Belarus
Vitebsk Regional Diagnostic Center
Vitebsk, Belarus
Vitebsk Regional Clinical Hospital
Vitebsk, Belarus
University Clinicl Center Sarajevo
Sarajevo, Bosnia and Herzegovina
UMHAT Sveti Georgi
Plovdiv, Bulgaria
Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum
Sofia, Bulgaria
Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead
Sofia, Bulgaria
Acibadem City Clinic Tokuda Hospital
Sofia, Bulgaria
St Ivan Rilski University Multiprofile Hospital For Active Treatment
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment Alexandrovska EAD
Sofia, Bulgaria
Military Medical Academy Multiprofile Hospital for Active Treatment Sofia
Sofia, Bulgaria
University of Alberta
Edmonton, Alberta, Canada
Royal Jubilee Hospital
Victoria, British Columbia, Canada
Ottawa Hospital
Ottawa, Ontario, Canada
Recherche Sepmus Inc.
Greenfield Park, Quebec, Canada
Ch Osijek
Osijek, Croatia
University Hospital Center Zagreb
Zagreb, Croatia
Fakultní nemocnici Brno
Brno, Czechia
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia
Nemocnice Jihlava
Jihlava, Czechia
Fakultni Nemocnice Ostrava
Ostrava-Poruba, Czechia
Pardubicka krajska nemocnice a s
Pardubice, Czechia
Vseobecna Fakultní Nemocnice
Prague, Czechia
FN Motol
Prague, Czechia
Krajska zdravotni, a.s. - Nemocnice Teplice, o.z.
Teplice, Czechia
Suomen Terveystalo Tampere
Tampere, Finland
Mehilainen NEO
Turku, Finland
Hopital Pellegrin CHU Bordeaux
Bordeaux, France
CHU Clermont-Ferrand - Hopital Gabriel Montpied
Clermont-Ferrand, France
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.